Most Read Articles
14 Mar 2017
Asian prostate cancer patients may show a significant reduction in bone mineral density (BMD) 12 months after androgen deprivation therapy (ADT) with no difference between those on continuous combined androgen block (CAB) and those on gonadotropin-releasing hormone (GnRH) agonist monotherapy, a new study shows.

Refining the role of combination therapy for the medical management of benign prostatic hyperplasia

15 Jun 2017
At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
14 Mar 2017
Asian prostate cancer patients may show a significant reduction in bone mineral density (BMD) 12 months after androgen deprivation therapy (ADT) with no difference between those on continuous combined androgen block (CAB) and those on gonadotropin-releasing hormone (GnRH) agonist monotherapy, a new study shows.